One-Year Outcomes of the SAVE Study:<u>S</u>irolimus as a Therapeutic<u>A</u>pproach for U<u>VE</u>itis

Abstract

The SAVE Study illustrates for the first time the application of local formulations of sirolimus in non-infectious intermediate, posterior, and pan-uveitis. Subconjunctival/Intravitreal sirolimus may help to control inflammation while offering better tolerability/safety profiles than systemic therapies, including immunosuppressants and corticosteroids.